Concepedia

Efficacy and safety of stapokibart (CM310) in adults with moderate-to-severe atopic dermatitis: A multicenter, randomized, double-blind, placebo-controlled phase 3 trial

Yan Zhao, Litao Zhang, Jianzhong Zhang

Journal of the American Academy of Dermatology · 2024 · 29 citations · 3 references

Open access

Concepts

Life SciencesDermatologyImmunologyAllergyHypersensitivityImmunopharmacologyAllergen ImmunotherapyAllergic Skin DiseasesAtopic DermatitisPatch TestingAtopic Dermatitis ImmunopathologyAtopic Dermatitis PharmacotherapyAtopic Dermatitis TreatmentPlacebo-controlled Efficacy Assessment

References

3

The efficacy and safety of dupilumab in Chinese patients with moderate‐to‐severe atopic dermatitis: a randomized, double‐blind, placebo‐controlled study*

Yan Zhao, Liming Wu, Qianjin Lu et al. · British Journal of Dermatology · 2021 · 71 citations · Full text

Medicine, Dermatology, Immunology +13

The prevalence and year lived with disability of atopic dermatitis in China: Findings from the global burden of disease study 2019

Wenlan Dong, Jing An, Miao Yu et al. · World Allergy Organization Journal · 2021 · 50 citations · Full text

Public Health, Dermatology, Health Sciences +17

Efficacy and safety of CM310 in moderate-to-severe atopic dermatitis: A multicenter, randomized, double-blind, placebo-controlled phase 2b trial

Yan Zhao, Jianzhong Zhang, Bin Yang et al. · Chinese Medical Journal · 2023 · 35 citations · Full text

Medicine, Dermatology, Immunology +14